ERBB2 and ovarian carcinoma: Preclinical studies have demonstrated efficacy in using anti-HER2 monoclonal antibody trastuzumab conjugated to IR700 in the treatment of ovarian cancer peritoneal metastases in mouse models and demonstrated effective cell killing of peritoneal implants [15].